Download biomedica product list
Breast Cancer
Breast Cancer – the most common cancer worldwide
Breast cancer (BC) is the most commonly occurring cancer in women and the most common cancer overall. Although it is mostly found in women, it can affect men as well. Breast tissue in men can also become malignant. Though male BCs are rare and occur in 1% of all BCs, men are often diagnosed at a more advanced stage. The delay in seeking medical attention often results in late presentation and poor prognosis.
October is breast cancer month – raising global awareness on risks, the importance of screenings, and the options of treatment.
Related links
Further readings
Wilkinson L et al., Br J Radiol. 2022. PMID: 34905391; PMCID. Full text
Abstract
Breast cancer is now the most commonly diagnosed cancer in the world. The most recent global cancer burden figures estimate that there were 2.26 million incident cases in 2020 and the disease is the leading cause of cancer mortality in women worldwide. The incidence is strongly correlated with human development, with a large rise in cases anticipated in regions of the world that are currently undergoing economic transformation. Survival, however, is far less favourable in less developed regions. There are a multitude of factors behind disparities in the global survival rates, including delays in diagnosis and lack of access to effective treatment. The World Health Organization’s new Global Breast Cancer Initiative was launched this year to address this urgent global health challenge. It aims to improve survival across the world through three pillars: health promotion, timely diagnosis, and comprehensive treatment and supportive care.
Trapani D et al., Cancer Treat Rev. 2022. PMID: 35074727.
Cancer research
Prognostic exploratory biomarkers
Circulating biomarkers have the potential to provide valuable insight into disease progression.
Discover Biomarker ELISA kits for cancer research – developed and manufactured by Biomedica
regulator of tumor biology – expressed by endothelial cells – isoform-specific receptors for VEGF – checkpoint target – association with poor prognosis in BC patients.
extracellular matrix protein – novel therapeutic target – marker of glioma malignancy and potential tumor recurrence – high serum levels associated with a poor survival in BC patients.
glycoprotein – emerging clinical biomarker and therapeutic target in cancer – association with cancer progression and the bone metastases.
contribution to development of bone metastases an –in earlier stages of cancer influence on tumor biology.
Leucine-rich alpha-2-glycoprotein 1 – LRG1 – involved in pathogenic angiogenesis in cancer – wide spread in the microenvironment of numerous tumors – contributes to vascular dysfunction – potential therapeutic target.
ANG2 – ANGPT2 – glycoprotein – drives vessel growth – immune target – involved in resistance to anti-VEGF therapy – possible predictive and prognostic biomarker for immune checkpoint therapy.
important cytokine during breast cancer progression – IL6 triggers activation of STAT2 in breast tumors – soluble factor IL6 could be used for early diagnosis of BC or prevent development of metastasis to the bone.
Vascular growth factor – potent cytokine that induces tumor angiogenesis – subtype VEGFA and VEGF Receptor -2 are therapeutical targets.
Further information on our products can be found on our website
International agency for research on cancer – WHO